Summary of effective production approval documents in China (as of February 7, 2015)

As of February 7, 2015, the total number of domestic document numbers monitored by Xianda data 3.0 is 173594, belonging to 6725 enterprises respectively Among them, there are 168981 domestic approvals and 5568 production enterprises It is worth noting that there are two enterprises with their names registered as "-", "," "," in the national database, among which "-" corresponds to the production approval number of "gyzz h20045612", "gyzz h20065908", "gyzz h20065909" and "gyzz h20065910"; and "corresponds to" gyzz h13020607 " Please go to worship Kazakhstan if you have time According to the statistics of the number of manufacturers with effective production approval, Jiangsu Province has the largest number of manufacturers, followed by Guangdong and Shandong The top ten provinces have more than 200 manufacturing enterprises If the statistics are based on the number of production approvals, the first is Jilin Province, the second is Guangdong Province, the third is Jiangsu Province, and the number of top three approvals is more than 10000 (see Figure 1-1 and Figure 1-2) There are 1112 enterprises in China with more than 50 production approvals (including 50), and 429 enterprises with more than 100 production approvals (including 100) The province with the largest number of enterprises with more than 50 production approvals is Jilin Province, with 106 enterprises in total, followed by Guangdong Province with 85 enterprises, and Jiangsu Province with 75 enterprises in the third place Data source: Xianda data 3.0 can be obtained from the statistical summary of the number of production approvals corresponding to different product categories Jiangsu Province is a veritable chemical Province, with 9490 chemical approvals, accounting for 8.89% of the total number of chemical approvals in China (106720 in total) Jilin Province is a big province of traditional Chinese medicine, accounting for 12.16% of the total number of Chinese medicine approvals (60293 in total) Shanxi Province has the largest number of TCM injection approval documents, followed by Sichuan Province and Jiangsu Province Jiangsu Province has the largest number of exclusive TCM injection approvals, followed by Jilin Province The number of exclusive TCM injection approvals in each province is no more than 10 The number of approval documents for biological products in beishangguang accounts for 38.66% of the total number of approval documents for biological products in China (1891 in total) (see Figure 2) Data source: according to data 3.0 of Xianda, the number of production approval documents corresponding to the exclusive common name can be concluded and analyzed The number of production approval documents of Beijing's exclusive common name is the largest, followed by Guangdong and Jilin The province with the largest number of production approvals for exclusive dosage forms was Guangdong, followed by Beijing, and Jiangsu ranked third If the number of production approval documents is counted according to the exclusive specification, it is Guangdong first, Jilin second and Beijing third If the above approvals are in production, according to the current bidding mainstream rules, the product approvals of Guangdong, Beijing, Jilin and Jiangsu will be relatively competitive in the future bidding According to the statistics of treatment field, the production approval number of anti infective drugs in Guangdong Province is the largest, and that of anti infective exclusive dosage form is the largest in Jiangsu Province; the production approval of cephalosporin drugs in injection type is the largest in Guangdong Province, followed by Hainan Province, and then Jiangsu Province Jiangsu Province has the largest number of production approvals for cardiovascular system drugs, while Jiangsu Province has the largest number of exclusive dosage forms for cardiovascular system drugs The production approval number of respiratory system drugs in Jilin is the largest, and the exclusive dosage form of respiratory system drugs in Beijing is the largest The number of production approval and exclusive dosage forms of digestive system drugs and nervous system drugs are the largest in Jiangsu Province According to the statistics of dosage forms, Jiangsu Province has the largest number of production approval documents, followed by Guangdong Province and Shanghai city; injection is also the largest number of production approval documents in Jiangsu Province; inhaler is the largest number of production approval documents in Shandong Province, in fact, Guangdong Province and Jiangsu Province In terms of the national medical insurance catalog, Jiangsu Province has the largest number of corresponding approvals for medical insurance category A and B, followed by Guangdong Province Guangdong Province has the largest number of class a approval documents for exclusive dosage form medical insurance, while Jiangsu Province has the largest number of class B approval documents for medical insurance In terms of base drug catalogue, Guangdong Province is the province with the most production approval documents in the national base drug catalogue The provinces with the largest number of national basic drug approvals for exclusive dosage forms were obtained by Shandong, Guangdong and Beijing Summary: the frequency of the provinces in this report is roughly counted There are 21 times in Jiangsu, 20 times in Guangdong, 13 times in Jilin, and 7 times in Beijing and Shandong At present, Jiangsu, Guangdong and Jilin provinces have a large number of approvals without considering the actual production of production approvals The number of approvals only represents the glory of the province's registration in the past, and even reflects the serious homogenization of approvals in China The higher the number of approvals, the higher the market value At present, the number of approval documents can not be used as a reference for the number of new approval documents in the province in the future For example, in 2014, the top three approved production approval documents were Jiangsu, Zhejiang and Shandong; Jilin was not in the top ten Finally, I copied the following passage For the future trend of the value of drug approval, I would like to make a judgment as follows: it is suggested that entrepreneurs who are optimistic about the future of the pharmaceutical industry should buy at a low price, entrepreneurs who want to quit or contract the business of the pharmaceutical industry should sell at a high price, and entrepreneurs who have no idea should sell at a high price and buy at a low price.